Navigation Links
Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research

RSCI's Chairman expressed his concern that since few people can afford to travel outside the country for medical treatments, America needs to put more focus on approving ultra safe adult stem cell treatments to alleviate the suffering of millions diagnosed with so-called untreatable diseases.

Bangkok, Thailand (PRWEB) March 31, 2009 -- Don Margolis, founder of the world's first stem cell treatment company and chairman of the Repair Stem Cell Institute, today issued a statement which took strong exception to Washington's emphasis on embryonic stem cells over both Repair (Adult) Stem Cells and induced Pluripotent stem cells (iPS).

Margolis said, "This leads to one key question which no one in America seems to ask: Why is the FDA, which indiscriminately rushes unproven deadly drugs to AIDS patients, forbidding six million dying heart patients access to long-proven SAFE stem cell therapy?" Is it because heart patients don't count in politics while AIDS patients do? Or is there another reason why they allow drugs such as Vioxx and forbid risk-free stem cells?

Margolis added that Repair Stems Cells are right now, every week, improving dozens and dozens of lives all over the world. He emphasized that "Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular dystrophy, ataxia, autism, COPD, emphysema, Crohn's, and optic nerve disorders, among 100+ other conditions, are receiving successful stem cell treatments today on every continent but North America!"

"When the President lifted the partial ban on federal funding for embryonic stem cell research stem cell research, he did not mention that Embryonic Stem Cells (ESC) have never worked on humans or animals and never will," Margolis said. "He also didn't mention that Embryonic Stem Cells, when injected into your body, can cause deadly tumors as they have in thousands of lab animals."

Mr. Margolis pointed out that just five days before the ESC announcement, Dr. Bernadine Healy, former director of the National Institutes of Health, published an article in U.S. News & World Report which states, "To date, most of the stem cell triumphs that the public hears about involve the infusion of adult stem cells." Healy concluded that "during the first six weeks of Obama's term, several events reinforced the notion that embryonic stem cells . . . are obsolete."

In support of Dr. Healy's point, Margolis quoted three world-class embryonic research scientists. First was Dr. James Thomson, the godfather of embryonics: "It is more than ironic that the scientist who first isolated and cultured ESC once said 'embryonic stem cells are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.'" Margolis went on to note that "Dr. Thomson's observation is even truer today. The number of diseases treatable with RSC is rapidly approaching 200, while the ESC count still sits on zero, despite the efforts of a thousand ESC researchers on four continents not hindered by the Bush era regulations."

Margolis then discussed the recent extraordinary discovery of induced Pluripotent stem cells (iPS), which can easily replace the need for ESC. "The potential of iPS is so big," Margolis said, "that even Dr. Ian Wilmut, who led the team that cloned the famous Dolly the sheep, abandoned his license to attempt human cloning, stating that researchers 'may have achieved what no politician could: an end to the embryonic stem cell debate.'"

"And end it we must," Margolis added, "before billions more dollars are wasted while millions of patients are forced to sit on Death Row, waiting for 21st century alchemy to magically transform embryonic stem cells into repair stem cells."

In closing, Margolis quoted Dr. Colin McGuckin, a noted UK embryonic research leader at Newcastle U. before departing for more useful RSC research in France: "The best estimates of the embryonic scientists here at Newcastle is that embryonic stem cells may not be able to help people this side of 50 years. That's my lifetime. We can't wait that long.'"

Mr. Margolis agrees: "The real cost of embryonic research is not the wasted billions, but 50 more years of unnecessary suffering by those who can be helped today."

About The Repair Stem Cell Institute: The Repair Stem Cell Institute's mission is to educate and inform everyone about the rapid advances being made in Repair Stem Cell research, so all can intelligently exercise freedom of choice in medical care. If you, or a loved one, are seeking treatment for your "untreatable" medical condition, visit for our list of the eight most experienced and successful stem cell treatment centers in the world, as well as the standards we apply to them.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Repair Stem Cell Institute Weighs in on Reversal of Embryonic Stem Cell Policy
2. GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery
3. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
4. Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair
5. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
6. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
7. California State Senator Shelia Kuehls Leadership in Stem Cell Debate Praised and Embryonic Stem Cell Profiteers Criticized by Repair Stem Cell Institute Spokesman
8. Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Repair Stem Cell Institute Announces Science Advisory Board
11. Worldwide Center for Adult Stem Cell Education LLC Changes Name to The Repair Stem Cell Institute LLC
Post Your Comments:
Related Image:
Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific discoveries ... doctors and other healthcare providers face challenges in better ... and patients. In addition, as more children continue to ... patient,s adulthood and old age. John M. ... Children,s Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
Breaking Biology News(10 mins):